Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Randomized, Controlled, Observer Blind Phase II Study

NCT02316470 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT02316470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02316470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Randomized, Controlled, Observer Blind Phase II Study
Lead sponsor
Valneva Austria GmbH
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
October 31, 2015
Enrollment
500 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile